1,294,864 Shares in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC bought a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,294,864 shares of the company's stock, valued at approximately $20,698,000. Janus Henderson Group PLC owned 1.14% of Centessa Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. HighMark Wealth Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the second quarter worth approximately $840,000. TD Asset Management Inc lifted its position in Centessa Pharmaceuticals by 40.5% in the 2nd quarter. TD Asset Management Inc now owns 321,168 shares of the company's stock worth $2,900,000 after buying an additional 92,524 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Centessa Pharmaceuticals by 1.3% during the 2nd quarter. American Century Companies Inc. now owns 935,151 shares of the company's stock valued at $8,444,000 after acquiring an additional 12,031 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Centessa Pharmaceuticals in the second quarter worth $148,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Centessa Pharmaceuticals by 438.0% during the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock worth $18,024,000 after acquiring an additional 1,625,000 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CNTA shares. Morgan Stanley upgraded Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Oppenheimer reiterated an "outperform" rating and issued a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a report on Monday, September 16th. Guggenheim upped their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Finally, B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a "buy" rating and a $33.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $25.83.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the sale, the insider now owns 183,266 shares in the company, valued at $3,236,477.56. This trade represents a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Saurabh Saha sold 87,496 shares of the company's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the transaction, the chief executive officer now owns 575,661 shares of the company's stock, valued at $10,626,702.06. This trade represents a 13.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 462,624 shares of company stock valued at $7,763,698. Corporate insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock traded up $1.18 on Friday, reaching $18.67. 690,784 shares of the stock were exchanged, compared to its average volume of 682,048. The firm has a fifty day moving average price of $16.41 and a two-hundred day moving average price of $13.03. Centessa Pharmaceuticals plc has a twelve month low of $6.15 and a twelve month high of $18.77. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.46 billion, a PE ratio of -12.20 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. Sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.